| Description | NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor (IC50: 30 nM and 200 nM for basal and NO-stimulated enzyme activity). It is commonly used in the research of nitric oxide signaling pathways. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase (IC50: 17 nM and 20 nM). NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells (IC50: 30 nM). NS-2028 inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM). NS-2028 decreases vascular endothelial growth factor-induced angiogenesis and permeability. |
| In vitro | NS-2028 (10 μM; 30分钟) 通过抑制p38 MAPK的激活，降低VEGF诱导的EC迁移。NS-2028 (10 μM; 24小时) 与那些在载体存在下生长的细胞相比，抑制了25%的细胞数量[2]。 |
| In vivo | 在无血管的兔角膜中，NS-2028（p.o; 1 g/L; 8天）对VEGF颗粒植入的新血管形成有明显的抑制作用[2]。 |
| Target activity | sGC:30 nM |
| molecular weight | 269.05 |
| Molecular formula | C9H5BrN2O3 |
| CAS | 204326-43-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 250 mg/mL (929.20 mM), Sonication is recommended. |
| References | 1. Olesen SP, et al. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309. 2. Morbidelli L, et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R824-32. |